Instruction for use: Nazol

Trade name of the drug – Nazol

ATX code R01AA05 Oxymetazoline

Pharmacotherapeutic group:

Decongestant agent - alpha-agonists [alpha agonists]

Decongestant agent - alpha-agonists [decongestant]

The nosological classification (ICD-10)

J00 Acute nasopharyngitis [runny nose]

Viral rhinitis, Inflammation of the nasopharynx, Inflammatory diseases of the nose, purulent rhinitis, Nasal congestion, Nasal congestion with colds and flu, The difficulty of nasal breathing, The difficulty of nasal breathing for colds, Difficulty in nasal breathing, Difficulty in nasal breathing in colds, nasal, hypersecretion, cold, ARI with rhinitis phenomena, coryza, Acute rhinitis of various origins, Acute rhinitis with thick purulent mucous exudate, Acute nasopharyngitis, Swelling of the mucosa of the nasopharynx, Rhinitis, rhinorrhea, Infectious-inflammatory diseases of ENT organs, heavy cold, rhinopharyngitis, nasopharyngitis

J01 Acute sinusitis

Inflammation of the sinuses, Inflammatory diseases of the paranasal sinuses, Purulent inflammation of the paranasal sinuses, Infectious-inflammatory diseases of ENT organs, Infection of the sinuses, Combined sinusitis, Exacerbation of sinusitis, Acute inflammation of the paranasal sinuses, Acute bacterial sinusitis, Acute sinusitis in adults, Subacute sinusitis, acute Sinusitis, sinusitis

J06 Acute upper respiratory infections of multiple and unspecified

Frequent colds viral diseases, Infections of the upper respiratory tract, Acute respiratory disease influenza character, for colds Pain, Acute colds,Cold, respiratory infection,Seasonal colds, Pain in infectious and inflammatory diseases of the upper respiratory tract, Bacterial infections of the upper respiratory tract, Bacterial respiratory infections, Viral disease of the respiratory tract, Viral respiratory tract infections, Inflammatory disease of the upper respiratory tract, Inflammation of the upper respiratory tract disease, Inflammation of the upper respiratory tract illness with difficult sputum, Inflammatory airway disease, Secondary infections with colds, Shortness of sputum in acute and chronic respiratory diseases, Upper respiratory tract infection, Infections of the upper respiratory tract, Respiratory Tract Infections, Infections of the respiratory tract and lungs, Infectious-inflammatory diseases of the upper respiratory tract, Infectious-inflammatory diseases of the upper respiratory tract and ENT-organs, Infectious-inflammatory diseases of the upper respiratory tract in children and adults, Infectious-inflammatory diseases of the upper respiratory tract, Infectious inflammation of the airways,respiratory infection, Qatar upper respiratory tract, Catarrh of the upper respiratory tract, Catarrhal disease of the upper respiratory tract, Catarrhal symptoms of the upper respiratory tract, Coughing with a cold, SARS, ARI, ARI with rhinitis phenomena, Acute respiratory infection, Acute infectious and inflammatory disease of the upper respiratory tract, Acute respiratory disease, Sore throat or nose, Respiratory viral infections, Respiratory diseases, Respiratory infections, Recurrent respiratory infections, Secondary infection with influenza, cold in the chest, Feverish condition with flu usitis, acute sinusitis, genyantritis, purulent sinusitis

J31.0 Chronic Rhinitis

Hyperplastic chronic Rhinitis, polypoid rhinosinusitis, Atrophic rhinitis with crusting, Hypertrophic rhinitis, Runny fetid, Rhinitis hyperplastic, chronic Rhinitis, Rhinitis chronic atrophic fetid, Rhinitis chronic atrophic simple, Rhinitis chronic hypertrophic, Exacerbation of chronic rhinitis, Chronic atrophic rhinitis, Dry rhinitis

J32 Chronic sinusitis

Allergic rhinosinusopathy, purulent sinusitis, Catarrh nasopharyngeal area, Catarrh of the sinuses, Exacerbation of sinusitis, chronic Sinusitis

Composition

Spray nasal dosage

100 ml of 1 dose

active substance:

oxymetazoline hydrochloride 0.025 g 0.05 mg

Excipients:

0.02 g benzalkonium chloride 0.01 mg

7.5 g of Macrogol 400 3.75 mg

0.4 g of povidone 0.2 mg

3.75 g propylene glycol 7.5 mg

sodium dihydrogen phosphate dihydrate, 0.006 g 0.003 mg

sodium dihydrogen phosphate dihydrate 0.65 g 0.325 mg

Disodium edetate dihydrate 0.1 g 0.05 mg

Concentrated hydrochloric acid 0.003 g 0.0015 mg

Purified water 86.571 g 43.2855 mg

Pharmacological Properties of NazolPharmachologic effect
decongestant, alpha-agonists.

Dosage and Administration

Intranasal.

1 dose contains 0.025 mg of oxymetazoline hydrochloride.

Adults and children over 12 years - 2-3 doses in each nostril 2 times a day.

Children 6 to 12 years - 1 dose in each nostril 2 times a day.

Do not use the drug more than 2 times a day.

Duration of treatment is not recommended to use the drug for more than 3 days. Frequent or prolonged use of the drug sense of difficulty in nasal breathing may reappear or worsen. should stop treatment and seek medical attention if these symptoms.

When injected not throw back his head back and spray into the prone position.

release Form

Spray nasal dosage, 0.025 mg / dose. In HDPE bottle dispenser, a spray of polypropylene and polyethylene screw cap, 10 ml (150 doses). On the bottle label affixed. The bottle in the carton box.

Storage conditions of Nazol

The temperature is not higher than 25 ° C.

Keep out of the reach of children.
Shelf life of Nazol

3 years.

Do not use beyond the expiration date printed on the package.

Available without prescription.